Cell engineering and immunotherapy research are key approaches to the future of cancer treatment. The Center for Cell Engineering plays an integral role in this research, providing and developing the tools needed by investigators and clinicians to conduct innovative clinical trials.
The Center for Cell Engineering focuses on two major areas: immune engineering with a focus on T lymphocytes, dendritic cells, natural killer cells and artificial antigen presenting cells to stimulate the body’s immune response to cancer, and human stem cell research, with a dual focus on hematologic and neurologic disorders.
Below are some of the current protocols:
Clinical Investigation
| Project | Investigator(s) |
|---|---|
| An Evaluation of Toxicity and Therapeutic Effects of Epstein-Barr Virus (EBV)-Immune T Lymphocytes Derived from Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lympho-proliferative Diseases and Patients with Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases | Richard J. O’Reilly, MD |
| A Phase I Trial in Melanoma for Immune Responses to Antigen-Bearing Dendritic Cells in Patients with Malignancy | James W. Young, MD |
| A Phase I/II Trial for EBV-Sensitized Donor T Cells Transduced W/Dicistronic Retroviral Vector, Termed NIT, Encoding a Mutant Human Nerve Growth Factor Receptor and Herpes Simplex Virus Thymidine Kinase for the Treatment of EBV Lymphomas in Marrow Allograft Recipients, and in Patients with Genetic Immunodeficiencies | Richard J. O’Reilly, MD, Michel Sadelain, MD, PhD, and Isabelle Riviere, PhD |
| A Phase I Dose-Escalation Trial for Donor T Cells Sensitized with Pentadecapeptides of the CMV-PP65 Protein for the Treatment of CMV Infections Following Allogeneic Hematopoietic Stem Cell Transplants | Richard J. O’Reilly, MD, and Guenther Koehne, MD, PhD |
| A Phase I Trial for the Treatment of Purine Analog-Refractory Chronic Lymphocytic Leukemia Using Autologous T Cells Genetically Targeted to the B Cell-Specific Antigen CD19 | Renier J. Brentjens, MD, PhD, Isabelle Rivière, PhD, Michel Sadelain, MD, PhD, and David A. Scheinberg, MD, PhD |
| Phase II Trial of HLA Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant | Katharine C. Hsu, MD, PhD |
| A Phase I Dose Escalation Trial of WT1-Specific T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation | Richard J. O’Reilly, MD and Guenther Koehne, MD, PhD |
| A Pilot Trial to Assess the Feasibility and Safety of G-CSF Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients with Beta-Thalassemia Major | Farid Boulad, MD, Isabelle Rivière, PhD, and Michel Sadelain, MD, PhD |
